Tumor Biology

, Volume 37, Issue 4, pp 4979–4990 | Cite as

Down-regulation of ribosomal protein S15A inhibits proliferation of human glioblastoma cells in vivo and in vitro via AKT pathway

  • Yiqun Yao
  • Yongjian Liu
  • Xiupeng Lv
  • Bin Dong
  • Feng Wang
  • Jun Li
  • Qiuping Zhang
  • Ruixue Xu
  • Yinghui XuEmail author
Original Article


Ribosomal protein s15a (RPS15A), a highly conserved cytoplasmic protein, promotes mRNA/ribosome interaction in translation. Recent evidence showed that RPS15A is essential for tumor growth. RPS15A expression level was measured in glioblastoma tissue samples and normal brain (NB) tissue samples. RPS15A RNAi stable cell line U87 and U251 was generated by the pLVTHM-GFP lentiviral RNAi expression system. The knockdown efficiency was confirmed by quantitative real-time PCR and western blot. Molecular mechanisms and the effect of RPS15A on cell growth and migration were investigated by using western blot, MTT assay, wound healing assay, transwell migration assay, and tumorigenesis in nude mice. Here, we report that RPS15A is overexpressed in human glioblastoma tumor tissues. RPS15A knockdown inhibits proliferation and migration of glioblastoma cells in vitro. Knocking down RPS15A leads to the level of p-Akt decrease and cell cycle arrested in G0/G1 phase in U87 and U251 cells. Furthermore, the growth of glioblastoma cell-transplanted tumors in nude mice is inhibited by transduction with Lv-shRPS15A. Our findings indicate that RPS15A promotes cell proliferation and migration in glioblastoma for the first time. RPS15A might play a distinct role in glioblastoma and serve as a potential target for therapy.


Glioma Glioblastoma RPS15A Therapy AKT pathway 



The study was sponsored by the Natural Science Foundation of China (NSFC) (No. 81172180). Hospital IRB approval has been signed for the use of human samples. The authors also thank YZ Wang lab for donating the cell lines.

Compliance with ethical standards

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Hospital IRB approval has been signed for the use of human samples. Informed consent was obtained from all individual participants included in the study. All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.

Conflicts of interest



  1. 1.
    Chen T et al. Dasatinib reverses the multidrug resistance of breast cancer MCF-7 cells to doxorubicin by downregulating P-gp expression via inhibiting the activation of ERK signaling pathway. Cancer Biol Ther. 2015;16:106–14.CrossRefPubMedGoogle Scholar
  2. 2.
    Chen X, Meng Q, Wang C, Liu Q, Sun H, Huo X, et al. Protective effects of calycosin against CCl4-induced liver injury with activation of FXR and STAT3 in mice. Pharm Res. 2015;32:538–48.CrossRefPubMedGoogle Scholar
  3. 3.
    Lanzetta G, Campanella C, Rozzi A, Nappa M, Costa A, Fedele F. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res. 2003;23:5159–64.PubMedGoogle Scholar
  4. 4.
    Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML, et al. Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res. 1999;59:1820–4.PubMedGoogle Scholar
  5. 5.
    Arshad H, Ahmad Z, Hasan SH. Gliomas: correlation of histologic grade, Ki67 and p53 expression with patient survival. Asian Pacific J Cancer Prev: APJCP. 2010;11:1637–40.Google Scholar
  6. 6.
    Dellaretti M, Reyns N, Touzet G, Dubois F, Gusmao S, Pereira JL, et al. Diffuse brainstem glioma: prognostic factors. J Neurosurg. 2012;117:810–4.CrossRefPubMedGoogle Scholar
  7. 7.
    Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell. 2006;9:157–73.CrossRefPubMedGoogle Scholar
  8. 8.
    Akiyama N, Matsuo Y, Sai H, Noda M, Kizaka-Kondoh S. Identification of a series of transforming growth factor beta-responsive genes by retrovirus-mediated gene trap screening. Mol Cell Biol. 2000;20:3266–73.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Lian Z, Liu J, Li L, Li X, Tufan NL, Wu MC, et al. Human S15a expression is upregulated by hepatitis B virus X protein. Mol Carcinog. 2004;40:34–46.CrossRefPubMedGoogle Scholar
  10. 10.
    Xu M, Wang Y, Chen L, Pan B, Chen F, Fang Y, et al. Down-regulation of ribosomal protein S15A mRNA with a short hairpin RNA inhibits human hepatic cancer cell growth in vitro. Gene. 2014;536:84–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Xinmin Zhao, Lei Shen, Yu Feng, Hui Yu, Xianghua Xu, Jianhua Chang, Xuxia Shen, Jie Qiao, Jialei Wang. Decreased expression of RPS15A suppresses proliferation of lung cancer cells, Tumor Biol (2015); doi: 10.1007/s13277-015-3371-9Google Scholar
  12. 12.
    Hannemann J, Velds A, Halfwerk JB, Kreike B, Peterse JL, van de Vijver MJ. Classification of ductal carcinoma in situ by gene expression profiling. Breast Cancer Res: Bcr. 2006;8:R61.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD, et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell. 2010;17:98–110.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Yan W, Zhang W, Jiang T. Oncogene addiction in gliomas: implications for molecular targeted therapy. J Exp Clin Cancer Res: Cr. 2011;30:58.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Chan YL, Olvera J, Paz V, Wool IG. The primary structure of rat ribosomal protein S15a. Biochem Biophys Res Commun. 1994;200:1498–504.CrossRefPubMedGoogle Scholar
  16. 16.
    Kenmochi N, Kawaguchi T, Rozen S, Davis E, Goodman N, Hudson TJ, et al. A map of 75 human ribosomal protein genes. Genome Res. 1998;8:509–23.PubMedGoogle Scholar
  17. 17.
    Vladimirov SN, Ivanov AV, Karpova GG, Musolyamov AK, Egorov TA, Thiede B, et al. Characterization of the human small-ribosomal-subunit proteins by N-terminal and internal sequencing, and mass spectrometry. Europ J Biochem/Febs. 1996;239:144–9.CrossRefGoogle Scholar
  18. 18.
    Zeller KI, Jegga AG, Aronow BJ, O'Donnell KA, Dang CV. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003;4:R69.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Bonham-Smith PC, Moloney MM. Nucleotide and protein sequences of a cytoplasmic ribosomal protein S15a gene from Arabidopsis thaliana. Plant Physiol. 1994;106:401–2.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Bonham-Smith PC, Oancia TL, Moloney MM. Cytoplasmic ribosomal protein S15a from Brassica napus: molecular cloning and developmental expression in mitotically active tissues. Plant Mol Biol. 1992;18:909–19.CrossRefPubMedGoogle Scholar
  21. 21.
    Liu AW, Cai J, Zhao XL, Jiang TH, He TF, Fu HQ, et al. ShRNA-targeted MAP4K4 inhibits hepatocellular carcinoma growth. Clin Cancer Res: An Official J Am Assoc Cancer Res. 2011;17:710–20.CrossRefGoogle Scholar
  22. 22.
    Zheng L, Liang P, Li J, Huang XB, Liu SC, Zhao HZ, et al. ShRNA-targeted COMMD7 suppresses hepatocellular carcinoma growth. PLoS One. 2012;7:e45412.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Lavoie C, Tam R, Clark M, Lee H, Sonenberg N, Lasko P. Suppression of a temperature-sensitive cdc33 mutation of yeast by a multicopy plasmid expressing a Drosophila ribosomal protein. J Biol Chem. 1994;269:14625–30.PubMedGoogle Scholar
  24. 24.
    Schreiber M, Muller WJ, Singh G, Graham FL. Comparison of the effectiveness of adenovirus vectors expressing cyclin kinase inhibitors p16INK4A, p18INK4C, p19INK4D, p21(WAF1/CIP1) and p27KIP1 in inducing cell cycle arrest, apoptosis and inhibition of tumorigenicity. Oncogene. 1999;18:1663–76.CrossRefPubMedGoogle Scholar
  25. 25.
    Swarbrick A, Lee CS, Sutherland RL, Musgrove EA. Cooperation of p27(Kip1) and p18(INK4c) in progestin-mediated cell cycle arrest in T-47D breast cancer cells. Mol Cell Biol. 2000;20:2581–91.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, et al. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia. 2003;17:590–603.CrossRefPubMedGoogle Scholar
  27. 27.
    Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, et al. Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review). Int J Oncol. 2003;22:469–80.PubMedGoogle Scholar
  28. 28.
    Zhang, X., Shi, H., Tang, H., Fang, Z., Wang, J., and Cui, S. miR-218 inhibits the invasion and migration of colon cancer cells by targeting the PI3K/Akt/mTOR signaling pathway. Int J Mol Med (2015).Google Scholar
  29. 29.
    Yuan Y, Du W, Wang Y, Xu C, Wang J, Zhang Y, et al. Suppression of AKT expression by miR-153 produced anti-tumor activity in lung cancer. International Journal of Cancer. J Int Du Cancer. 2015;136:1333–40.CrossRefGoogle Scholar
  30. 30.
    Yi, X. P., Han, T., Li, Y. X., Long, X. Y., and Li, W. Z. Simultaneous silencing of XIAP and survivin causes partial mesenchymal-epithelial transition of human pancreatic cancer cells via the PTEN/PI3K/Akt pathway. Mol Med Rep (2015).Google Scholar
  31. 31.
    Geng J, Li X, Zhou Z, Wu CL, Dai M, Bai X. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer. Cancer Lett. 2015;359:275–87.CrossRefPubMedGoogle Scholar
  32. 32.
    Singh M, Savitz SI, Hoque R, Gupta G, Roth S, Rosenbaum PS, et al. Cell-specific caspase expression by different neuronal phenotypes in transient retinal ischemia. J Neurochem. 2001;77:466–75.CrossRefPubMedGoogle Scholar
  33. 33.
    Wang ST, Liu JJ, Wang CZ, Lin B, Hao YY, Wang YF, et al. Expression and correlation of Lewis y antigen and TGF-beta1 in ovarian epithelial carcinoma. Oncol Rep. 2012;27:1065–71.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Yiqun Yao
    • 1
  • Yongjian Liu
    • 2
  • Xiupeng Lv
    • 1
  • Bin Dong
    • 1
  • Feng Wang
    • 2
  • Jun Li
    • 1
  • Qiuping Zhang
    • 3
  • Ruixue Xu
    • 1
  • Yinghui Xu
    • 1
    Email author
  1. 1.Department of Neurosurgery, First Affiliated HospitalDalian Medical UniversityDalianChina
  2. 2.Department of interventional therapy, First Affiliated HospitalDalian Medical UniversityDalianChina
  3. 3.Department of Pathology, First Affiliated HospitalDalian Medical UniversityDalianChina

Personalised recommendations